09966 ALPHAMAB-B
- 5.190
- -0.040-0.76%
ALPHAMAB-B News
Corning Jerry Pharmaceuticals-B (09966.HK): Dual Antibiotic Technology Leader Focuses on Developing Innovative Oncology Therapies
Bank International: The target price for the “neutral” rating for Corning Jerry Pharmaceuticals (09966) fell to HK$7.4
Corning Jerry Pharmaceuticals (9966.HK): PDAC Phase III Data Reading Delays KN046 Uncertainty Rises Again; Target Price Lowers
BOC International: Maintaining Corning Jerry Pharmaceuticals-B (09966) “Neutral” Rating Target Price of HK$9
Corning Jerry Pharmaceuticals (9966.HK): ESMO updates multiple data but there is still uncertainty about core asset development; maintains neutral ratings
Corning Jerry Pharmaceuticals (9966.HK): 1H23 losses have narrowed, but there is still uncertainty about core product development and commercialization; target prices have been lowered
Corning Jerry Pharmaceuticals (9966.HK): KN046 development faces uncertainty and downgraded to neutral
BOCOM International: Maintaining Corning Jerry Pharmaceuticals' (09966) “Buy” Rating Target Price of HK$16.22
Corning Jerry Pharmaceutical-B (09966.HK): The first product was successfully commercialized and the core pipeline progressed steadily
Corning Jerry Pharmaceutical-B (09966.HK) Follow-up Analysis Report: Innovative Differentiated Modeling KN046 Is Expected to Impact Pancreatic Cancer FIC
Corning Jerry Pharmaceutical-B (9966.HK): Excellent clinical data on dual antibodies, research and development progressed smoothly
Corning Jerry Pharmaceutical-B (9966.HK): Core Dual Antibody Shines at SABCS Conference; Target Price Raised
Corning Jerry Pharmaceutical-B (09966.HK): The first commercial product, rapid release of core clinical trials, has entered a critical stage
Corning Jerry Pharmaceutical-B (9966.HK) Interim Report Commentary: KN035 Revenue Meets Expectations of the Epidemic Situation; Catalysts Abundant in the Second Half of the Year
Corning Jerry Pharmaceutical-B (09966.HK): KN046 and KN026 have registered clinical trials continue to push new molecules into the clinical stage one after another
Corning Jerry Pharmaceutical-B (9966.HK): Progressive release of envolizumab in the research pipeline is about to enter a harvest period
Corning Jerry (9966.HK): One of the leaders in the domestic dual resistance field, with thick and thin hair under multiple technical arrangements
Corning Jerry (9966.HK): KN046 1L SQNSCLC requires the provision of OS data and is expected to be delayed by 10 months
Corning Jerry Pharmaceutical-B (09966.HK): KN046 achieved major clinical breakthroughs in the first year of commercialization
Corning Jerry Pharmaceutical-B (9966.HK) Annual Report Review: The company entered the first year of commercialization, and the research pipeline gradually ushered in a harvest period
Analysis
Price Target
No Data
